Specific interactions between the Candida albicans ABC transporter Cdr1p ectodomain and a d-octapeptide derivative inhibitor

• Published in: Molecular microbiology 2012-08, Vol.85 (4), p.747-767
• Main Authors: Niimi, Kyoko, Harding, David R. K., Holmes, Ann R., Lamping, Erwin, Niimi, Masakazu, Tyndall, Joel D. A., Cannon, Richard D., Monk, Brian C.
• Format: Article
• Language: English
• Subjects: ABC transporters; Biological and medical sciences; Candida albicans; Candida albicans - enzymology; Drug Resistance, Fungal; Enzyme Inhibitors - metabolism; Fundamental and applied biological sciences. Psychology; Fungal Proteins - antagonists & inhibitors; Fungal Proteins - genetics; Fungal Proteins - metabolism; Fungi; Inhibitor drugs; Membrane Transport Proteins - genetics; Membrane Transport Proteins - metabolism; Microbial Sensitivity Tests; Microbiology; Miscellaneous; Models, Molecular; Mutation; Mycology; Oligopeptides - metabolism; Protein Binding; Protein Conformation; Saccharomyces cerevisiae; Suppression, Genetic; Yeast
• ISSN: 0950-382X; 1365-2958
• DOI: 10.1111/j.1365-2958.2012.08140.x

Summary Overexpression of the Candida albicans ATP‐binding cassette transporter CaCdr1p causes clinically significant resistance to azole drugs including fluconazole (FLC). Screening of a ∼ 1.89 × 106 member d‐octapeptide combinatorial library that concentrates library members at the yeast cell surface identified RC21v3, a 4‐methoxy‐2,3,6‐trimethylbenzenesulphonyl derivative of the d‐octapeptide d‐NH2‐FFKWQRRR‐CONH2, as a potent and stereospecific inhibitor of CaCdr1p. RC21v3 chemosensitized Saccharomyces cerevisiae strains overexpressing CaCdr1p but not other fungal ABC transporters, the C. albicans MFS transporter CaMdr1p or the azole target enzyme CaErg11p, to FLC. RC21v3 also chemosensitized clinical C. albicans isolates overexpressing CaCDR1 to FLC, even when CaCDR2 was overexpressed. Specific targeting of CaCdr1p by RC21v3 was confirmed by spontaneous RC21v3 chemosensitization‐resistant suppressor mutants of S. cerevisiae expressing CaCdr1p. The suppressor mutations introduced a positive charge beside, or within, extracellular loops 1, 3, 4 and 6 of CaCdr1p or an aromatic residue near the extracytoplasmic end of transmembrane segment 5. The mutations did not affect CaCdr1p localization or CaCdr1p ATPase activity but some increased susceptibility to the CaCdr1p substrates FLC, rhodamine 6G, rhodamine 123 and cycloheximide. The suppressor mutations showed that the drug‐like CaCdr1p inhibitors FK506, enniatin, milbemycin α11 and milbemycin β9 have modes of action similar to RC21v3.